Financial publications

 

The financial publications section contains the Company’s annual and quarterly reports, corporate presentations held at Investor Relations events as well as the Company’s financial guidance and financial key figures. Further information regarding the Company’s business model and its business segments can be found in the 'About' section of this website.

 

Financial Reports

Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.

 

Financial Reports Archive

2020
2019

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the acquisition of Just.Bio

2018

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2018 results

2017

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2017 results

Conference Call/Webcast regarding the acquisition of Aptuit

2016

Financial Statements

Conference Call/Webcast regarding strategic collaboration with Celgene

Conference Call/Webcast regarding the offer to acquire Cyprotex

2014

Financial Statements

Conference Call/Webcast announcing negotiations on major collaboration with Sanofi

2011

Annual Report

Financial Statements

Conference call Webcast announcing licence argeement with Roche

Conference call and Webcast announcing the acquisition of Compound Focus, Inc.

Conference call and Webcast announcing the acquisition of Kinaxo

2010

Financial Statements

Conference call and Webcast announcing the alliance with MedImmune

Third Quarter Report

Half Year Report

Conference call and Webcast announcing the acquisition of DeveloGen

First Quarter Report

2009

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2008

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2007

Annual Report

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2006

Annual Report

Financial Statements According to HGB

Third Quarter Report

Second Quarter Report

First Quarter Report

2005

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

New Segmental P&L Statements

2004

Third Quarter Report

Second Quarter Report

First Quarter Report

2003

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2002

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2001

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2000

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

Oxford Asymmetry International plc 2000 Interim Statement

Oxford Asymmetry International plc 2000 Interim Statement

1999

Annual Report

Third Quarter Report

Oxford Asymmetry International plc Annual Report 1999

Guidance 2020

Guidance 2020
Actual 2019
Group revenues from contracts with customers 
€ 440 - 480 m2)
€ 446.4 m
Unpartnered R&D expenses
Approx. € 40 m 
€ 37.5 m
Adjusted Group EBITDA1)

€ 100 - 120 m2)

€ 123.1 m
Group revenues from contracts with customers   
Guidance 2020 € 440 - 480 m2)
Actual 2019 € 446.4 m
Unpartnered R&D expenses  
Guidance 2020 Approx. € 40 m 
Actual 2019 € 37.5 m
Adjusted Group EBITDA1)  
Guidance 2020

€ 100 - 120 m2)

Actual 2019 € 123.1 m

1) EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. Adjusted EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

2) Despite the loss of € 20 m subsidy payments from Sanofi and significantly ramping up J.POD® capacities

 

Financial key figures 2019 according to IFRS

2019
2018
19|18 in %
Results:
Revenues from contracts with customers
T€
446,437
375,405
19
R&D expenses
T€
(58,432)
(35,619)
64
Operating result
T€
62,594
77,463
(19)
Adjusted Group EBITDA1)
T€
123,143
95,457
29
Net income
T€
37,228
84,056
(56)
Balance sheet data:
Total stockholders' equity
T€
477,029
424,880
12
Capital expenditure2)
T€
31,322
27,867
12
Cash, cash equivalents and investments3)
T€
320,022
149,449
>100
Balance sheet total
T€
1,180,912
771,883
53
Operating cash flow
T€
42,216
156,240
(73)
Personnel data:
Employees as of 31 December
3,030
2,617
16
Per share:
Result (basic/diluted)
0,25/0,25
0.57/0.56
(56)/(55)
Results:  
2019
2018
19|18 in %
Revenues from contracts with customers  
T€
2019 446,437
2018 375,405
19|18 in % 19
R&D expenses  
T€
2019 (58,432)
2018 (35,619)
19|18 in % 64
Operating result  
T€
2019 62,594
2018 77,463
19|18 in % (19)
Adjusted Group EBITDA1)  
T€
2019 123,143
2018 95,457
19|18 in % 29
Net income  
T€
2019 37,228
2018 84,056
19|18 in % (56)
 
2019
2018
19|18 in %
Balance sheet data:  
2019
2018
19|18 in %
Total stockholders' equity  
T€
2019 477,029
2018 424,880
19|18 in % 12
Capital expenditure2)  
T€
2019 31,322
2018 27,867
19|18 in % 12
Cash, cash equivalents and investments3)  
T€
2019 320,022
2018 149,449
19|18 in % >100
Balance sheet total  
T€
2019 1,180,912
2018 771,883
19|18 in % 53
Operating cash flow  
T€
2019 42,216
2018 156,240
19|18 in % (73)
 
2019
2018
19|18 in %
Personnel data:  
2019
2018
19|18 in %
Employees as of 31 December  
2019 3,030
2018 2,617
19|18 in % 16
 
2019
2018
19|18 in %
Per share:  
2019
2018
19|18 in %
Result (basic/diluted)  
2019 0,25/0,25
2018 0.57/0.56
19|18 in % (56)/(55)

1) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
2) Cash-relevant purchase of tangible and intangible assets
3) Cash and cash equivalents and investments

 

 

Investor Presentations

Please find below various presentations held at investor conferences or during investor calls available for your download.

Contact us

Gabriele Hansen

SVP, Corporate Communications, Marketing & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Anja Ben Lekhal

Investor Relations Associate

T + 49 40 56081 210 F +49 40 56081 222 vCard
TOP